Table 3.

Fine-Gray multivariable analysis for locoregional and distant failure outcomes

	Locoregional Failure			Distant Failure
	aHR	95% CI	P	aHR	95% CI	P
Cisplatin
> / = 5 Cycles	Reference			Reference
< 5 Cycles	1.61	0.46–5.58	0.46	4.55	1.19–17.3	0.03
Gender
Male	Reference			Reference
Female	0.12	0.02–0.73	0.02	< 0.001	< 0.001- < 0.001	< 0.001
Smoker
Never	Reference			Reference
Former	6.38	0.24–170.72	0.27	5.69	0.57–57.1	0.14
Current	0.78	0.04–14.22	0.87	3.34	0.34–32.9	0.3
Age
< 65	Reference			Reference
65 or older	0.49	0.07–3.34	0.46	0.14	0.02–0.88	0.04
KPS
90–100	Reference			Reference
< 90	1.81	0.55–6.00	0.33	1.74	0.23–13.3	0.59
Race
White	Reference			Reference
Other	4.78	0.69–32.93	0.11	0.14	0.02–0.78	0.03
BMI
Normal	Reference			Reference
Underweight	64.4	7.90–524.98	< 0.001	< 0.001	< 0.001–0.001	< 0.001
Overweight	2.6	0.63–10.77	0.19	23	2.54–208	0.005
Obese	2.04	0.48–8.76	0.34	12.1	1.31–113	0.03
Not available	0.003	< 0.001–0.40	0.02	< 0.001	< 0.001–0.02	< 0.001
Site
Oropharynx	Reference			Reference
Larynx	0.98	0.15–6.52	0.99	2.75	0.27–28.2	0.39
Oral cavity	< 0.001	< 0.001–0.12	0.01	1500	22.2–1.01e5	< 0.001
Other	1.53	0.20–11.87	0.68	1.78	0.15–20.8	0.65
T staging
1–2	Reference			Reference
3–4	18.7	1.80–194.53	0.01	5.33	1.20–23.7	0.03
N staging
0–1	Reference			Reference
2–3	2.34	0.28–20.00	0.44	19.7	3.64–106	< 0.001
HPV
Negative	Reference			Reference
Positive	2.18	0.13–36.41	0.59	1.1	0.20–5.95	0.91
Not available	5.39	0.33–88.75	0.24	0.5	0.07–3.57	0.49

aHR Adjusted hazards ratio, 95% CI 95% Confidence interval, BMI Body mass index, KPS Karnofsky performance status, HPV Human papillomavirus